Get started
monsRUS

Novavax +50%

Long
Novavax, Inc. (NASDAQ:NVAX)  
monsRUS  
NASDAQ:NVAX   Novavax, Inc.
Trend Analysis Technical Indicators Fundamental Analysis
4
0
trendanalysis indicator fundamental
The final analysis of the U.K. trial showed that the vaccine was 96.4% effective against "mild, moderate, and severe disease caused by the original COVID-19 strain.
Vaccine efficacy was 86.3% against the fast-spreading U.K. variant (B.1.1.7/501Y.V1). Overall vaccine efficacy was 89.7%.

Хочешь хороших денег – умей выжидать
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.